China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
HARBIN, China, Aug. 14 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. (''China Sky One Medical'' or ''the Company'') , a leading fully integrated pharmaceutical company producing external use, over-the-counter drugs in the People's Republic of China ("PRC"), today announced that it successfully developed a nasal spray for the treatment and prevention of rheumatic disease.
Heilongjiang Tianlong Pharmaceutical, Inc. (''Tianlong''), a wholly-owned subsidiary of China Sky One Medical, Inc., recently completed research and development for the spray, which includes the active ingredients Naphazoline Hydrochloride Chlorpheniramine Maleate and Benzalkonium Bromide. Rheumatic diseases are shown in common sympathies and characterized by joint inflammation. There are currently only five other manufacturers of the spray in China and China Sky One has obtained the necessary approvals for production.
''We are very excited about the development of this spray, which serves a huge market in China,'' said Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical, Inc. ''We expect to launch the spray in the fourth quarter of 2008, and estimate that sales will add $500,000 to revenue in the fourth quarter.''
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (''TDR'') and Harbin First Bio- Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
CONTACT: Company Contact: China Sky One Medical, Inc., Mr. Yu-Bo Hao,
Board Secretary, +86-451-53994069, or china_sky_one@yahoo.cn; Investor
Relations Contact: CCG Investor Relations, Mr. Crocker Coulson, President,
+1- 646-213-1915, or crocker.coulson@ccgir.com; Mr. Richard Micchelli,
Financial Writer, +1-646-454-4516, or richard.micchelli@ccgir.com
Web site: http://www.skyonemedical.com/
http://www.ccgir.com/